Clinical Trial

Trilaciclib Combing Chemotherapy in the Neoadjuvant Treatment of Osteosarcoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated December 3, 2024 (before its estimated July 2025 completion). Its status may not reflect the trial's current state.
Summary
To evaluate the clinical application value in bone marrow protection of Trilaciclib in the neoadjuvant treatment of stage II/III classic osteosarcoma in combination with pirarubicin and lobaplatin.
Trial Details
NCT Number NCT06714383
Lead Sponsor Peking University People's Hospital
Conditions Osteosarcoma
Enrollment 50 participants
Start Date 2024-11-13
Primary Completion 2025-07 (estimated)
Study Completion 2025-11 (estimated)
Updated on ClinicalTrials.gov 2024-12-03